Introducing OmniSeq INSIGHT®
All Solid Tumors
Preferred: FFPE Block
Alternate: 20 unstained slides
Typical Turnaround Time
Hours of operation: Monday-Friday excluding holidays, and TAT is 10 business days
Expanded Insight = Increased Options
Marker-Driven FDA Approved Therapy Associations
Markers with NCCN Therapeutic Guidance Evidence
Markers with Clinical Trial Associations
Industry-guided content for a comprehensive view of cancer-related fusion genes, detecting common and novel fusions.
Detect Fusions Missed By DNA-seq
Effectively Match Patients to the Right Trial
MOLECULAR + IMMUNE PROFILING = MORE PATIENT OPTIONS
PROFILING THE ACTIONABLE CANCER GENOME
Comprehensive Trial Matching Across the Actionable Cancer Genome for Solid Tumors
Expertly Curated Clinical Trial Matching Assessing Biomarker-Based Eligibility Criteria, Multi-Arm Study Designs and Treatment Context Assertions
PROFILING THE TUMOR MICROENVIRONMENT
Increase Clinical Trial Options by Targeting Biomarkers Involved in the Adaptive Immune System
Understanding the Anti-Cancer Immune Response is Critical to Adapt Therapies to the Cancer Phenotype.
OmniSeq Delivers the Only Test Matching Trials to Tumor-Immune Mechanisms and Low-Expressing Genes Involved in Inflammatory Signaling
Key Clinical Report Features
Solid Tumor Genomic and Immune Profiling
- Detected mutations, rearrangements (fusions/splice variants), copy number changes (gain/loss), TMB, MSI, and PD-L1 (IHC)
- RNA-based detection of fusions and splice variants
- Highly expressed immunotherapy targets for clinical trial identification
- Pertinent negatives for the tested tumor type
- Matched therapies, resistance associations and geographically focused clinical trials
- Potential cancer-associated germline variants flagged
At-a-glance and detailed marker clinical significance and efficacy evidence for matched FDA-approved targeted therapies, immunotherapies, and clinical trials.
Personalized Marker Details
Comprehensive annotation of clinically relevant markers for precision medicine selection and support of molecular tumor boards
Trust a test provider ISO13485:2016 CERTIFIED to design, develop and deliver DNA and RNA testing for the medical management and identification of genomic and immune biomarkers in oncology.